Overall and progression-free survival of Afro-Caribbean men with metastatic castration-resistant prostate cancer (mCRPC) - MULTIGNER-QUENEL - Evaluation des expositions et recherche épidémiologique sur l'environnement, la reproduction et le développement (3ERD) Accéder directement au contenu
Article Dans Une Revue Prostate Année : 2022

Overall and progression-free survival of Afro-Caribbean men with metastatic castration-resistant prostate cancer (mCRPC)

Résumé

Introduction Several studies in the Caucasian population have shown the benefit of using docetaxel, abiraterone, or enzalutamide for patients with metastatic prostate cancer at the castration-resistant stage (mCRPC). However, there are no strong data for men of African ancestry. The objective of this study was to estimate the overall and progression-free survival of patients according to these treatments at the mCRPC stage. Patients and Methods This was a monocentric retrospective study that consecutively included 211 men with mCRPC between June 1, 2009 and August 31, 2020. The primary end point was overall survival (OS). The secondary end point was progression-free survival. Kaplan-Meier survival and Cox proportional hazard analyses were performed. Results The present study included 180 patients for analyses. There was no difference in OS (log-rank test = 0.73), with a median follow-up of 20.7 months, regardless of the treatment administered in the first line. Men with mCRPC who received hormonotherapy (abiraterone or enzalutamide) showed better progression-free survival than those who received docetaxel (log-rank test = 0.004), with a particular interest for abiraterone hazard ratio (HR) = 0.51 (95% confidence interval: 0.39-0.67). The patient characteristics were similar, except for bone lesions, irrespective of the treatment administered in the first line. After univariate then multivariate analysis, only World Health Organization status and metastases at diagnosis were significantly associated with progression. Conclusion Our results suggest the use of hormonotherapy (abiraterone or enzalutamide) with a tendency for abiraterone in first line for men with African ancestry at the mCRPC stage.
Fichier non déposé

Dates et versions

hal-03476790 , version 1 (13-12-2021)

Identifiants

Citer

Pierre-Gilles Vestris, Gilles Gourtaud, Cedric Senechal, Yvanne Sadreux, Virginie Roux, et al.. Overall and progression-free survival of Afro-Caribbean men with metastatic castration-resistant prostate cancer (mCRPC). Prostate, 2022, 82 (2), pp.269-275. ⟨10.1002/pros.24270⟩. ⟨hal-03476790⟩
16 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More